Asarina Pharma Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
ASAP
- Share Price
-
$0.08
- (As of Monday Closing)
Asarina Pharma General Information
Description
Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.
Contact Information
Website
www.asarinapharma.com
Formerly Known As
Umecrine Mood
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
- Karolinska Institutet Science Park
- Fogdevreten 2
- 171 65 Solna
- Sweden
+46 08-524 000 00
Asarina Pharma Timeline
Asarina Pharma Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.08 | $0.08 | $0.07 - $0.46 | $1.88M | 22.6M | 19.9K | -$0.07 |
Asarina Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 494 | 810 | 1,975 | 6,544 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (1,477) | (1,394) | (4,369) | (8,970) |
| Net Income | (1,377) | (1,309) | (3,686) | (8,162) |
| Total Assets | 727 | 1,616 | 3,355 | 8,324 |
| Total Debt | 0 | 0 | 586 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Asarina Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Asarina Pharma Patents
Asarina Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019249932-A1 | Gaba-a antagonists for treating substance withdrawal disorders | Inactive | 05-Apr-2018 | 0000000000 | |
| CA-3094026-A1 | Gaba-a antagonists for treating substance withdrawal disorders | Pending | 05-Apr-2018 | 0000000000 | |
| EP-3773599-A1 | Gaba-a antagonists for treating substance withdrawal disorders | Inactive | 05-Apr-2018 | 0000000000 | |
| US-20210161915-A1 | Gaba-a antagonists for treating substance withdrawal disorders | Inactive | 05-Apr-2018 | 000000000 | |
| EP-3579842-A4 | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor | Pending | 10-Feb-2017 | A61P25/14 | 0 |
Asarina Pharma Executive Team (6)
Asarina Pharma Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Marianne Kock | Asarina Pharma | Director | 000 0000 |
| Otto Skolling | Asarina Pharma | Board Member & Chief Business Officer | 000 0000 |
| Paul de Potocki | Self | Chairman | 000 0000 |
| Torbjörn Bäckström MD | Self | Founder & Chairman- Scientific Advisory Board | 000 0000 |
Asarina Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Asarina Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|